Dr Luke Pratsides
Head of Medical
MBBS MSc MRCGP MFCI
Wegovy stimulates nerve receptors in the brain that control appetite, so you feel less hungry and have fewer cravings. Additionally, it stimulates the release of insulin from pancreatic beta cells, as GLP-1 is present in both the pancreas and the brain. Implementing behavioural change strategies alongside the treatment is known to be an effective method for weight loss.1
Wegovy contains the active ingredient semaglutide, which mimics a natural hormone that suppresses your appetite and reduces food cravings.1
Clinical trials have proven that the drug drives healthier choices and leads to weight loss.1
Keeps you full between meals
Reduces cravings
Non-addictive
Easy to administer
Reduces risk of cardiovascular disease2
Numan’s Weight Loss Programme is developed by a team of specialists who understand the complex challenges of weight management. Drawing on the latest in metabolic research, appetite regulation, and psychology, our experts bring together innovative treatments and personalised strategies designed for sustainable results.
Our approach includes the use of Wegovy, a GLP-1 receptor agonist, which curbs cravings making it easier to stay on track.1 Paired with guidance from healthcare professionals and lifestyle coaches, the programme adapts to your unique needs at every step.
Health coaching is at the heart of our programme, designed to create lasting lifestyle changes. Paired with Wegovy’s appetite-regulating effects, our coaches provide guidance on building practical, sustainable habits in nutrition, exercise, sleep, and mindset.
Wegovy helps manage cravings, while our coaches enhance these benefits, offering advice on balanced meals, enjoyable movement, and effective routines for better health. Together, they give you the support needed to make meaningful progress and maximise your results.
Numan’s Weight Loss Programme tackles obesity with a fresh perspective, understanding it as a medical condition shaped by external factors.3 Our approach goes beyond conventional advice, incorporating treatments to provide a solid foundation for lasting lifestyle adjustments.
With obesity impacting a significant portion of the UK population, we offer a comprehensive solution that combines medical support with tailored guidance. By addressing the core drivers of weight gain, our programme empowers you to achieve and sustain a healthier weight with expert-led, compassionate care.
1 (*) Based on semaglutide over 68 weeks. Wilding, John PH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine (2021).
2 Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., & SELECT Trial Investigators. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
3 Lee A, Cardel M, Donahoo WT. Social and Environmental Factors Influencing Obesity. [Updated 2019 Oct 12]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278977/
Answer a few simple questions to get the treatment you need.